Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer

被引：3
作者：
Hudis, CA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 01期
关键词：
breast cancer; chemotherapy; HER2; survival; trastuzumab;
D O I：
10.1038/ncponc0401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 4 条
[1]   Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group [J].
Marty, M ;
Cognetti, F ;
Maraninchi, D ;
Snyder, R ;
Mauriac, L ;
Tubiana-Hulin, M ;
Chan, S ;
Grimes, D ;
Antón, A ;
Lluch, A ;
Kennedy, J ;
O'Byrne, K ;
Conte, P ;
Green, M ;
Ward, C ;
Mayne, K ;
Extra, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4265-4274
[2]   Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].
Piccart-Gebhart, MJ ;
Procter, M ;
Leyland-Jones, B ;
Goldhirsch, A ;
Untch, M ;
Smith, I ;
Gianni, L ;
Baselga, J ;
Bell, R ;
Jackisch, C ;
Cameron, D ;
Dowsett, M ;
Barrios, CH ;
Steger, G ;
Huang, CS ;
Andersson, M ;
Inbar, M ;
Lichinitser, M ;
Láng, I ;
Nitz, U ;
Iwata, H ;
Thomssen, C ;
Lohrisch, C ;
Suter, TM ;
Ruschoff, J ;
Süto, T ;
Greatorex, V ;
Ward, C ;
Straehle, C ;
McFadden, E ;
Dolci, MS ;
Gelber, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672
[3]   Cardiac dysfunction in the trastuzumab clinical trials experience [J].
Seidman, A ;
Hudis, C ;
Pierri, MK ;
Shak, S ;
Paton, V ;
Ashby, M ;
Murphy, M ;
Stewart, SJ ;
Keefe, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1215-1221
[4]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792
1